NCT03179930 Combination Therapy With Entinostat and Pembrolizumab in Relapsed and Refractory Lymphomas Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT03179917 Pembrolizumab and Involved Site Radiation Therapy for Early Stage Relapsed or Primary Refractory Hodgkin Lymphoma Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT03179436 Study of Quavonlimab (MK-1308) in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-1308-001) Status COMPLETED Phase PHASE1/PHASE2
NCT03175172 Evaluation of CRS-207 With Pembrolizumab in Previously Treated Malignant Pleural Mesothelioma (MPM) Status TERMINATED Phase PHASE2
NCT03168438 Letetresgene Autoleucel Engineered T Cells Alone and in Combination With Pembrolizumab in NY-ESO-1 Positive Multiple Myeloma Status TERMINATED Phase PHASE1
NCT03167151 Pembrolizumab in Intermediate Risk Recurrent Non-muscle Invasive Bladder Cancer (NMIBC) Status TERMINATED Phase PHASE1/PHASE2
NCT03166254 Personalized Therapeutic Anti-tumor Vaccine With Pembrolizumab and Standard of Care Chemotherapy in Squamous Non-Small Cell Lung Cancer and Extensive Stage Small Cell Lung Cancer Status WITHDRAWN Phase PHASE1
NCT03163992 Pembrolizumab in Advanced Hepatocellular Carcinoma as Second-line Treatment After Failure of Sorafenib Status COMPLETED Phase PHASE2
NCT03161431 SX-682 Treatment in Subjects With Metastatic Melanoma Concurrently Treated With Pembrolizumab Status ACTIVE_NOT_RECRUITING Phase PHASE1
NCT03160079 Blinatumomab & Pembrolizumab for Adults With Relapsed/Refractory B-cell ALL With High Marrow Lymphoblasts Status COMPLETED Phase PHASE1/PHASE2
NCT03157089 Testing Afatinib in Combination With Pembrolizumab in Patients With Squamous Cell Carcinoma of the Lung Status COMPLETED Phase PHASE2
NCT03153410 Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas Status COMPLETED Phase EARLY_PHASE1
NCT03153202 Study to Evaluate the Safety and Preliminary Efficacy of Ibrutinib and Pembrolizumab in Patients With Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymphoma (MCL) Status ACTIVE_NOT_RECRUITING Phase PHASE1/PHASE2
NCT03150329 Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL. Status ACTIVE_NOT_RECRUITING Phase PHASE1
NCT03149822 Study of Pembrolizumab and Cabozantinib in Patients With Metastatic Renal Cell Carcinoma Status COMPLETED Phase PHASE1/PHASE2
NCT03149029 Abbreviated MAPK Targeted Therapy Plus Pembrolizumab in Melanoma Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT03145961 A Trial Using ctDNA Blood Tests to Detect Cancer Cells After Standard Treatment to Trigger Additional Treatment in Early Stage Triple Negative Breast Cancer Patients Status UNKNOWN Phase PHASE2
NCT03142334 Safety and Efficacy Study of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (MK-3475-564/KEYNOTE-564) Status COMPLETED Phase PHASE3
NCT03138889 Bempegaldesleukin and Pembrolizumab With or Without Chemotherapy in Locally Advanced or Metastatic Solid Tumors Status TERMINATED Phase PHASE1/PHASE2